Wells Fargo initiated coverage of Alkermes (ALKS) with an Overweight rating and $44 price target. The firm contends that alixorexton will work in narcolepsy and that near-term catalysts will unlock value in NT2, narcolepsy type 2, and IH, idiopathic hypersomnia, the analyst tells investors in a research note. NT2 data this fall are key, as success here could give investors a solid anchor to a potentially large market with less competition from Takeda (TAK), Wells Fargo stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Hold Rating: Balancing Strong Performance with Alixorexton Uncertainties
- Alkermes’ Hold Rating: Balancing Strong Revenue Growth with Orexin Program Uncertainties
- Alkermes Reports Strong Q2 2025 Financial Results
- Alkermes Earnings Call: Strong Growth and Promising Trials
- Alkermes price target lowered to $33 from $35 at BofA